About 10% of individuals develop a post-traumatic stress disorder (PTSD) after experiencing a traumatic event. PTSD is a disabling psychiatric disorder, characterised by exaggerated fear responses towards reminders of the traumatic event. Although generally effective, a substantial part of PTSD patients do not fully benefit from existing psychotherapies. Oxytocin has been suggested as a promising pharmacologica, adjuvant for medication-enhanced psychotherapy in PTSD. Saskia Koch investigates the therapeutic potential of oxytocin in PTSD.
S.B.J. Koch, Boosting Oxytocin after Trauma: Effects of Oxytocin on Fear Neurocircuitry in Patients with Post-Traumatic Stress Disorder.
Prof. D.J. Veltman
Prof. M. Olff
Dr M. van Zuiden
This event is open to the public.